|本期目录/Table of Contents|

[1]郑晓阳.Sphk/S1P 轴与S1PR 在心肌纤维化中的研究进展[J].慢性病学杂志,2019,20(03):364-367.
点击复制

Sphk/S1P 轴与S1PR 在心肌纤维化中的研究进展(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
20
期数:
2019年03期
页码:
364-367
栏目:
综 述
出版日期:
2019-04-10

文章信息/Info

Title:
-
作者:
郑晓阳
河南圣德医院，河南 信阳 464000
Author(s):
-
关键词:
鞘氨醇激酶/1-磷酸鞘氨醇轴; 鞘氨醇激酶; 1-磷酸鞘氨醇; 1-磷酸鞘氨醇受体; 心肌纤维化
Keywords:
-
分类号:
R542.2
DOI:
-
摘要:
心肌纤维化是循环系统或心脏自身在心脏缺血、全身性疾病、药物或其他损伤性刺激的影响下出现的间质 性心肌胶原网的数量和质量变化。其是多种心血管疾病的共同病理结果，与心律失常、心功能不全和心力衰竭等 多种疾病的发生有关，探索心肌纤维化相关通路对于防治心肌纤维化等心血管疾病具有重要意义。有研究显示， 鞘氨醇激酶/1-磷酸鞘氨醇（Sphk/S1P）轴和1-磷酸鞘氨醇受体（S1PR）在心肌纤维化中发挥重要作用。本文 主要对SphK/S1P轴介导的下游信号通路及S1PR在纤维化中的作用进行综述，并简要介绍S1PR亚型调节剂在 心功能和纤维化治疗方面的进展。
Abstract:
-

参考文献/References:


[1] Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis [J]. Cell Mol Life Sci, 2014,71(4):549-574.
[2] Klingberg F, Hinz B, White ES. The myofibroblast ma-trix: implications for tissue repair and fibrosis [J]. J Pathol,2013,229(2):298-309.
[3] Travers JG, Kamal FA, Robbins J,et al. Cardiac fibrosis: the fibroblast awakens [J]. Circ Res, 2016,118(6):1021-1040.
[4] Lindsey ML, Iyer RP, Jung M,et al. Matrix metallopro-teinases as input and output signals for post-myocardial in-farction remodeling [J]. J Mol Cell Cardiol, 2016,91:134-140.
[5] Tomasek JJ, Gabbiani G, Hinz B,et al. Myofibroblasts and mechano- regulation of connective tissue remodeling [J]. Nat Rev Mol Cell Biol, 2002,3(5):349-363.
[6] Travers JG, Kamal FA, Robbins J,et al. Cardiac fibrosis: the fibroblast awakens [J]. Circ Res, 2016,118(6):1021-1040.
[7] Chen C, Li R, Ross RS,et al. Integrins and integrin-re-lated proteins in cardiac fibrosis [J]. J Mol Cell Cardiol, 2016,93:162-174.
[8] Lighthouse JK, Small EM. Transcriptional control of cardi-ac fibroblast plasticity [J]. J Mol Cell Cardiol, 2016,91:52-60.
[9] Bader M. Tissue renin- angiotensin- aldosterone systems: targets for pharmacological therapy [J]. Annu Rev Pharma-col Toxicol, 2010,50(1):439-465.
[10] Leask A. Getting to the heart of the matter: new insights into cardiac fibrosis [J]. Circ Res, 2015,116(7):1269-1276.
[11] Maceyka M, Harikumar KB, Milstien S,et al. Sphingo-sine-1- phosphate signaling and its role in disease [J]. TrendsCell Biol,2012,22(1):50-60.
[12] Lynch KR, Thorpe SB, Santos WL. Sphingosine kinase inhibitors: a review of patent literature (2006-2015) [J]. Expert Opin Ther Pat,2016,26(12):1409-1416.
[13] Liu H, Toman RE, Goparaju SK,et al. Sphingosine Ki-nase type 2 is a putative BH3- only protein that induces apoptosis [J]. J Biol Chem, 2003,278(41):40330-40336.
[14] Means CK, Brown JH. Sphingosine-1-phosphate receptor-signalling in theheart [J]. Cardiovasc Res, 2009,82(2):193-200.
[15] Ebenezer DL, Fu P, Natarajan V. Targeting sphingosine-1-phosphate signaling in lung diseases [J]. PharmacolTher, 2016,168:143-157.
[16] Karliner JS. Sphingosine kinase and sphingosine1- phos-phate in the heart: A decade of progress [J]. Biochim Bio-phys Acta,2013,1831(1):203-212.
[17] Takuwa Y, Ikeda H, Okamoto Y,et al. Sphingosine-1-phosphate as a mediator involved in development of fibrot-ic diseases [J]. Biochim Biophys Acta, 2013,1831(1):185-192.
[18] Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function [J]. Physiol Rev, 2007,87(4):1285-1342.
[19] Nistri S, Pini A, Sassoli C,etal. Relaxin promotes growth and maturation of mouse neonatal cardiomyocytes in vitro: clues for cardiac regeneration [J]. J Cell Mol Med, 2012,16 (3):507-519.
[20] Alessia F, Barbara R, Federica P,et al. Role of sphingo-sine kinase/S1P axis in ECM remodeling of cardiac cells elicited by relaxin [J]. Mol Endocrinol, 2015,29(1):53-67.
[21] Takuwa N, Ohkura S, Takashima S,et al. S1P3-mediat-ed cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species [J]. Cardiovasc Res, 2010, 85(3):484-493.
[22] 周芬.1-磷酸鞘氨醇信号通过TGF-β-纤维化促进心肌梗死后心 肌重构[D].第四军医大学,2014.
[23] Hait NC, Allegood J, Maceyka M,et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phos-phate [J]. Sci,2009,325(5945):1254-1257.
[24] Pang M, Zhuang S. Histone deacetylase: a potential thera-peutic target for fibrotic disorders [J]. J Pharmacol Exp Ther,2010,335(2):266-272.
[25] Yu H, Duan P, Zhu H,et al. miR-613 inhibits bladder cancer proliferation and migration through targeting SphK1 [J]. Am J Transl Res, 2017,9(3):1213-1221.
[26] Zhao Y, Ling Z, Hao Y,et al. MiR-124 acts as a tumor suppressor by inhibiting the expression of sphingosine ki-nase 1 and its downstream signaling in head and neck squamous cell carcinoma [J]. Oncotarget, 2017,8(15):25005-25020.
[27] Vestri A, Pierucci F, Frati A,et al. Sphingosine 1-phos-phate receptors: do they have a therapeutic potential in car-diac fibrosis [J]. Front Pharmacol,2017,8:296.
[28] Shea BS, Brooks SF, Fontaine BA,et al. Prolonged ex-posure to sphingosine 1-shosphate receptor-1 agonists ex-acerbates vascular leak, fibrosis, and mortality after lung injury [J]. Am J Respir Cell Mol Biol, 2010,43(6):662-673.
[29] Camerer E, Regard JB, Cornelissen I,et al. Sphingosine-1- phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice [J]. J Clin Invest, 2009,119(7):1871-1879.
[30] Yung BS, Brand CS, Xiang SY,et al. Selective coupling of the S1P3 receptor subtype to S1P-mediated RhoA acti-vation and cardioprotection [J]. J Mol Cell Cardiol, 2016, 103:1-10.
[31] Lowe NG, Swaney JS, Moreno KM,etal. Sphingosine-1-phosphate and sphingosine kinase are critical for transform-ing growth factor-β-stimulated collagen production by car-diac fibroblasts [J]. Cardiovasc Res,2009,82(2):303-312.
[32] Santosgallego CG, Vahl TP, Goliasch G,et al. Sphingo-sine- 1- phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia/re-perfusion [J]. Circul,2016,133(10):954-966.
[33] Aytan N, Choi JK, Carreras I,et al. Fingolimod modu-lates multiple neuroinflammatory markers in a mouse mod-el of Alzheimer’s disease [J]. Sci Rep, 2016,6:24939.
[34] Keul P, van Borren MM, Ghanem A,et al. Sphingosine-1-phosphate receptor1 regulates cardiac function by modu-lating Ca 2+ sensitivity and Na + /H + exchange and mediates protection by ischemic preconditioning [J]. J Am Heart As-soc, 2016,5(5):e003393.
[35] Vessey DA, Li L, Honbo N,et al. Sphingosine 1-phos-phate is an important endogenous cardioprotectant released by ischemic pre- and postconditioning [J]. Am J Physiol Heart Circ Physiol,2009,297(4):H1429-H1435.
[36] Satsu H, Schaeffer MT, Guerrero M,et al. A sphingosine 1-phosphate receptor2selective allosteric agonist [J]. Bioorg Med Chem,2013,21(17):5373-5382.
[37] Cattoretti G, Mandelbaum J, Lee N,et al. Targeted dis-ruption of the S1P2 sphingosine 1- phosphate receptor gene leads to diffuse large B-cell lymphoma formation [J]. Cancer Res,2009,69(22):8686-8692.

备注/Memo

备注/Memo:
作者简介：郑晓阳，硕士研究生，主治医师，研究方向： 心血管疾病 通信作者：郑晓阳，E-mail：1196762634@qq.com
更新日期/Last Update: 2019-03-28